A#2527 DAHLIAS, P2 Nipocalimab: Anti-FcRn Ab in Ro+ SjD IV 5 or 15 mg/kg Prim Endpt: 15 mg/kg has ClinESSDAI at w24 -6.4 v -3.7 PBO p=0.002 Improv dryness, fatigue, pain Better unstim salivary flow Best response in higher Ab titer pts Safety data good #ACRBest #ACR24 @RheumNow https://t.co/O7zahPul66

• https://x.com/ericdeinmd/status/1858514479035650062/photo/1
• https://x.com/ericdeinmd/status/1858514479035650062/photo/1
• https://x.com/ericdeinmd/status/1858514479035650062/photo/1

Phase 2 DAHLIA study in Sjogrens Anti-neonatal Fc receptor an “nipocalimab” w/remarkably encouraging results clinESSDAI significantly better at wk24, notably met QOL domains as well Finally getting good news in SjS! #ACR24 @RheumNow #ACRbest Abst#2527 https://t.co/e3uQmqJZ1o

• https://x.com/EBRheum/status/1858514973355286783/photo/1
• https://x.com/EBRheum/status/1858514973355286783/photo/1
• https://x.com/EBRheum/status/1858514973355286783/photo/1
• https://x.com/EBRheum/status/1858514973355286783/photo/1

I have no doubt many of our RA patients will take GLP-1 agonists in the future. Here's some data @UCLA showing significant differences in not just body weight and HbA1c, but pain. Will be fascinating to see what it does for grumbling disease activity! #ACR24 ABST2259 @RheumNow https://t.co/HdOPACEo3A

• https://x.com/drdavidliew/status/1858491323172671539/photo/1

Renal biopsies, while painful, remain the gold standard for diagnosing and classifying lupus nephritis. But what if there are less-invasive methods? In this article, I highlight key abstracts exploring innovative approaches. https://t.co/ZInKmVS2Gn @RheumNow #ACR24

• Beyond the Needle: Redefining the Assessment of Lupus Nephritis | RheumNow

Upadacitinib in Behcet's disease - would be very much welcomed, and this open label 8 patient pilot from China is encouraging. We saw similar data for tofacitinib before @ARD_BMJ: https://t.co/YlAQVXpnTY JAKi (?generic) could be a fantastic option! #ACR24 ABST2515 @RheumNow https://t.co/65friNLUOK

• A pilot study of tofacitinib for refractory Behçet’s syndrome
• https://x.com/drdavidliew/status/1858481726164783377/photo/1

Post hoc analysis of SPIRIT H2H evaluated nail involvement as a measure of ttnt response in PsA. -Pts with nail involvement treated with IXE or ADA had higher SJC and TJC improvement vs those without involvement at W12, W24 and W52. -IXE achieved rapid response for DAPSA-LDA as… https://t.co/SR36qCthQo https://t.co/hI3tD5hATJ

• https://x.com/i/web/status/1858299028125212898
• https://x.com/AdelaCastro222/status/1858299028125212898/photo/1

My ramblings on the SELECT-GCA study and predictions of the place of upadacitinib in clinical practice in GCA are up now on RheumNow #ACR24 @RheumNow https://t.co/DR5VgVmdse

• SELECT-GCA: Efficacy and Safety of Upadacitinib | RheumNow

We saw evidence for JAK use in GCA this conference... what about IL-1 inhibition? Double-blind RCT: Anakinra vs. PBO w/ similar GC taper in GCA pt NO difference in relapse rate at 26, 52 wks despite addition of Anakinra @RheumNow #ACR24 Abst1699 https://t.co/gUb0gGJjTG

• https://x.com/Dr_Brian_MD/status/1858268878658514984/photo/1

VERY exciting SLE update from Fava et al. Machine learning used to generate urinary protein panel predictive of intra-renal inflammation BETTER than serum biomarkers C3, C4, dsDNA Also monitoring tool for renal response. Outstanding. @RheumNow #ACRbest #ACR24 https://t.co/YXgKrSU4UQ

• https://x.com/Dr_Brian_MD/status/1858272797983977838/photo/1
• https://x.com/Dr_Brian_MD/status/1858272797983977838/photo/1

Phase 2 RCT of MK2 inhibitor did not show clinical efficacy at week 12 in active AS pts compared to PBO. There are still unmet needs for additional therapeutics in pts with AS that not respond to current therapies. Abst#1760 #ACR24 @RheumNow https://t.co/cXv8HYr0Xr

• https://x.com/AdelaCastro222/status/1858263006217400826/photo/1
• https://x.com/AdelaCastro222/status/1858263006217400826/photo/1